Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma

    Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma

    June 10, 2022
    June 10, 2022

    Download the PDF